

Application No.: 10/609,147  
Confirmation No.: 6705  
Filing Date: June 27, 2003  
Examiner: Paul V. Ward  
Group Art Unit: 1614  
Applicants: Knegt et al.  
For: CASPASE INHIBITORS AND USES THEREOF

September 5, 2006  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER FOR SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT**

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.
- ☒ Copies of references Citation Nos. **B1-B5; C1-C7** are attached.
- ☐ Copy(ies) of references Citation No(s). \_\_\_\_\_ was/were filed in application U.S. Application No(s). \_\_\_\_\_ filed \_\_\_\_\_, from which this application claims priority under 35 U.S.C. § 120.
- ☐ A copy of the International Search Report received in the corresponding PCT Application No. \_\_\_\_\_ is attached herewith.
- (b) ☒ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☒ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart

Applicants: Ronald Knegt  
Application No.: 10/609,147

foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or

☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

(d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and


☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or

☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and

☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.


☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. \_\_\_50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,

  
\_\_\_\_\_  
Jennifer G. Che, Reg. No. 58,035  
Agent for Applicants  
Lisa A. Dixon, Reg. No. 40,995  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel.: (617) 444-6535  
Fax.: (617) 444-6483  
Customer No. 27916

I hereby certify that this correspondence and any documents referred to as attached hereto are being deposited with the U.S. Postal Service with sufficient postage as Express Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 5, 2006.

Lisa M. Romano

  
\_\_\_\_\_  
Signature



Modified Form 1449/PTO				Application Number		10/609,147	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Filing Date		June 27, 2003	
				First Named Inventor		Ronald Knegtel	
				Group Art Unit		1614	
				Examiner Name		Not Yet Assigned	
				Attorney Docket Number		VPI/02-110 US	
<b>U.S. PATENT DOCUMENTS</b>							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,756,466	26-May-1998	Bemis et al.			
	A2	4,728,647	1-Mar-1988	Benavides, et al.			
	A3	5,656,627	12-Aug-1997	Bemis et al.			
	A4	5,847,135	08-Dec-1998	Bemis et al.			
	A5	5,716,929	10-Feb-1998	Bemis et al.			
	A6	6,103,711	15-Aug-2000	Bemis et al.			
	A7	5,973,111	26-Oct-1999	Bemis et al.			
	A8	6,420,522	16-Jul-2002	Bemis et al.			
	A9	6,025,147	15-Feb-2000	Bemis et al.			
	A10	20030162993	28-Aug-2003	Mortimore et al.			
	A11	20040019017	29-Jan-2004	Mortimore et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B1	WO 96/40647 A1	Prototek Inc.	19-Dec-1996			
	B2	WO 98/16502 A1	Warner-Lambert Company	23-Apr-1998			
	B3	WO 98/16505 A1	Warner-Lambert Company	23-Apr-1998			
	B4	WO 2000/68188 A1	Texas Biotechnology Corporation	16-Nov-2000			
	B5	WO 2004/58718 A1	Vertex Pharmaceuticals Incorporated	15-July-2004			
<b>OTHER NON PATENT LITERATURE DOCUMENTS</b>							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Semple, G., et al. "Pyridone-Based Peptidomimetic Inhibitors of Interleukin-1 $\beta$ -Converting Enzyme (ICE)," <i>Bioorganic &amp; Medicinal Chem. Letters</i> , 7(10):1337-1342 (1997).					
	C2	Livingston, D.J. "In Vitro and In Vivo Studies of Ice Inhibitors," <i>J. of Cell. Biochem.</i> , 64(1):19-26 (1997).					
	C3	Hussain, M. I., et al. "Some New 2-Aryloxymethyl-3-alpha-substituted Carboxymethyl-6,8-substituted-4-Quinazolones As Possible Anticonvulsants," <i>Pharmazie</i> , 37(6):408-410 (1982).					
	C4	Hussain, M., Imtiaz, et al. "Some Newer Quinazolones as Possible Anticonvulsants," <i>J. Chem. Soc. Pak</i> , 6(4):211-215 (1984).					
	C5	Canonne, P., et al. "Synthesis of chiral 3-substituted 2,4(1H,3H)-quinazolinodiones," <i>Heterocycles</i> , 36(6):1305-1314 (1993).					
	C6	Gouilleux, L., et al. "Solid Phase Synthesis of Chiral 3-substituted Quinazoline-2, 4-diones," <i>Tetrahedron, Letters</i> , 37(39):7031-7034 (1996).					
	C7	Gordeev, M. F., et al. "A General and Efficient Solid Phase Synthesis of Quinazoline-2, 4-diones," <i>Tetrahedron Letters</i> , 38(10):1729-1732 (1997).					
Examiner Signature					Date Considered		

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.